Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
AQEMIA logo — Scale drug discovery with quantum-inspired physics and gener...

AQEMIA

Scale drug discovery with quantum-inspired physics and generative AI

Founded 2019 France France 84 employees Unknown Total: $115.18M AI, Biotechnology +3

General Information

Company Name AQEMIA
Founded Year 2019
Location France France +2
Founders / Decision Makers
Team member
Employees 84
Industries AI, Biotechnology, Life Sciences +2
Funding Stage Unknown
Social

Get notified when AQEMIA moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

New Partnership Sep 02, 2026

AQEMIA announced a collaboration with France Biotech, featuring its co-founder and CEO in the launch of France Biotech's new Parole d'Entrepreneur series.

Get alerts when AQEMIA shows new signals

AI Insight

Bounce Watch AI
2 months ago

AQEMIA is signaling an active growth and strategic refinement phase, evidenced by the simultaneous recruitment for 6 new positions and a significant 78.82% update to its website in June 2026. This concerted activity suggests the company is deploying its recent substantial funding to expand its team and potentially rebrand or launch new offerings, indicating a pivot towards accelerated market scaling and enhanced visibility.

Signal Types
Hiring Strategic Update
Strategic Labels
Team Expansion Strategic Refinement Growth Acceleration
Next Move: Product Launch
·
Impact: 8/10
·
Ideal For: Deeptech Biopharma VCs — Growth Stage

About AQEMIA

AQEMIA, founded in 2019, is a cutting-edge company at the intersection of AI and biotechnology, focusing on drug discovery through the use of quantum-inspired physics and generative AI. The company specializes in creating novel medicines to address significant diseases, particularly in the oncology space, and is known for seeking solutions beyond the capabilities of traditional R&D.

Headquartered in France, with additional operations in London, AQEMIA is part of the French Tech 120 program, highlighting its potential for global impact. The company's innovative platform has already led to several discovery successes and collaborations with top pharmaceutical firms, moving promising candidates toward in vivo optimization.

In its most recent financial milestone, AQEMIA secured a $7.40M grant investment led by France 2030 on April 1, 2025. This boost underscores investor confidence in AQEMIA's pioneering approach in the life sciences sector and its ongoing growth trajectory.

Taxonomy: Drug Discovery, Quantum-inspired Physics, Generative AI, Pharmaceutical R&D, TechBio, PharmaTech, Computational Chemistry, Oncology, AI Drug Discovery, Drug Design, Physics-based Technology, Atomic Scale Physics, Biopharma, Immuno-Oncology

Services & Products

AI-driven drug discovery
Development of next-generation medicines

Target Customers

Pharmaceutical companies Biotech researchers Healthcare providers

Funding Rounds & Investors (7)

View All
Funding Stage Amount Investors Lead Investors Date
Grant •••••• 1 •••• •••• 01 Apr 2025
Early VC •••••• 5
Investor Investor Investor Investor
•••• •••• 		01 Dec 2024
Series A •••••• 4
Investor Investor Investor
•••• •••• 		01 Jan 2024
Series A •••••• 3
Investor Investor
•••• •••• 		01 Oct 2022
Series A •••••• 2
Investor
•••• •••• 		01 Jan 2021

View All 7 Funding Rounds

Latest News

View All
Sanofi offers up to $140M in new collaboration with Aqemia — Tech
Sanofi offers up to $140M in new collaboration with Aqemia
Tech Jan 23, 2024
Gen AI and quantum to design new drugs: Paris-based Aqemia completes €60m Series A — Sifted
Gen AI and quantum to design new drugs: Paris-based Aqemia completes €60m Series A
Sifted Feb 07, 2024
Deeptech VC Elaia teams up with European research labs to launch €120m seed fund — Sifted
Deeptech VC Elaia teams up with European research labs to launch €120m seed fund
Sifted Mar 14, 2024
As European dynamism gathers momentum, Elaia and partners double down with new deep tech fund — Techcrunch
As European dynamism gathers momentum, Elaia and partners double down with new deep tech fund
Techcrunch Mar 14, 2024
10 French startups to watch in 2024 — Tech
10 French startups to watch in 2024
Tech Mar 26, 2024
Cambridge startup analyses ‘multi-omics’ data to discover new heart drugs — Thenextweb
Cambridge startup analyses ‘multi-omics’ data to discover new heart drugs
Thenextweb Sep 10, 2024

AQEMIA Alternatives & Competitors

View All Alternatives
AQEMIA vs
Forma Therapeutics
Forma Therapeutics United States

Dedicated to transforming the lives of patients with rare hematologic diseases and cancers.

Series D
159 employees
Biotechnology, Health Care
Compare AQEMIA vs Forma Therapeutics
AQEMIA vs
PharmEnable Therapeutics
PharmEnable Therapeutics United Kingdom

Harnessing the power of chemical novelty, diversity and 3-dimensionality to develop innovative small...

Seed
14 employees
Biotechnology, Life Sciences
Compare AQEMIA vs PharmEnable Therapeutics
AQEMIA vs
Verseon
Verseon United States

Game-Changing Technology, Life-Changing Medicines

Unknown
23 employees
Biotechnology, Health and Wellness
Compare AQEMIA vs Verseon
View all alternatives

FAQ About AQEMIA

Scale drug discovery with quantum-inspired physics and generative AI
AQEMIA was founded in 2019.
AQEMIA is headquartered in France.
AQEMIA operates in the following industries: AI, Biotechnology, Life Sciences, Pharmaceutical, Machine Learning.
AQEMIA has approximately 84 employees.
AQEMIA has completed 7 funding rounds, raising a total of $115.18M. The latest funding stage is Unknown.
AQEMIA offers: AI-driven drug discovery, Development of next-generation medicines.
Top alternatives and competitors to AQEMIA include Forma Therapeutics, PharmEnable Therapeutics, Verseon, PharmEnable Therapeutics, Orbis Medicines. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
AQEMIA and Forma Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors AQEMIA and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy